Glycostem Therapeutics BV
🇳🇱Netherlands
- Country
- 🇳🇱Netherlands
- Ownership
- Holding
- Established
- 2007-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.glycostem.com
Registry of Patients Having Received oNKord®
Recruiting
- Conditions
- AML
- Interventions
- Drug: oNKord®Drug: Cyclophosphamide/Fludarabine (Cy/Flu)
- First Posted Date
- 2022-03-22
- Last Posted Date
- 2022-08-04
- Lead Sponsor
- Glycostem Therapeutics BV
- Target Recruit Count
- 50
- Registration Number
- NCT05290662
- Locations
- 🇩🇪
Medizinische Hochschule Hannover, Hannover, Germany
🇨🇭University Hospital Basel, Basel, Switzerland
A Trial to Evaluate the Safety and Efficacy of oNKord® in Subjects With Acute Myeloid Leukemia
Phase 1
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Drug: Cyclophosphamide-Fludarabine (Cy/Flu)Drug: oNKord®
- First Posted Date
- 2020-11-17
- Last Posted Date
- 2022-06-21
- Lead Sponsor
- Glycostem Therapeutics BV
- Target Recruit Count
- 33
- Registration Number
- NCT04632316
- Locations
- 🇧🇪
University Hospital Ghent, Ghent, Belgium
🇧🇪University Hospital Leuven, Leuven, Belgium
🇩🇪University Medical Center Hamburg-Eppendorf, Hamburg, Germany
© Copyright 2025. All Rights Reserved by MedPath